The late-stage pipeline, much of which is targeting MRSA, will generate revenues totaling nearly $2.0bn by 2019. However, Datamonitor predicts that this upside will be insufficient to offset the decline caused by genericization, and total seven major market sales will fall from $19.6bn in 2009 to $16.4bn in 2019, with a CAGR of -1.8%.
Your key questions answered
* Assess and quantify the market opportunity for antibacterials, from generics to high-priced hospital brands.
* Understand the changing market dynamics of antibacterial drugs and success factors for leading brands.
* Assess the impact of key issues affecting the antibacterials market; generic erosion and growing levels of resistance.
TABLE OF CONTENTS
About Datamonitor healthcare 2
About the Infectious Disease pharmaceutical analysis team 2
Executive Summary 3
Strategic scoping and focus 3
Datamonitor insight into the antibacterials market 3
Related reports 4
Upcoming related reports 4
CHAPTER 1 MARKET Definition and Overview 10
Market definition for this report 10
Countries and regions included in this report 10
Seven major market assessment 10
Class analysis 19
Brand analysis 21
Comparison with previous forecast 27
Rest of the World snapshot 30
CHAPTER 2 Brand Dynamics 34
Overview of competitive landscape 34
Levaquin/Cravit/Tavanic (levofloxacin; Johnson & Johnson/Daiichi Sankyo/Sanofi-Aventis) 40
Zosyn/Tazocin (piperacillin/tazobactam; Pfizer/Taisho Pharmaceutical) 43
Zyvox (linezolid; Pfizer) 45
Cubicin (daptomycin; Cubist Pharmaceuticals/Novartis/Merck & Co.) 49
Merrem/Meropen (meropenem; AstraZeneca/Dainippon Sumitomo) 53
Avelox/Octegra (moxifloxacin; Bayer/Merck & Co.) 56
Copyright©2010 PR Newswire.
All rights reserved